Positive Phase III Data For Tasocitinib Give Pfizer A Badly Needed Pipeline Lift
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer retains its lead in race to bring a novel oral RA drug to market
You may also be interested in...
Avanir Relying On PBA Drug Nuedexta For Success
Approved last year for pseudobulbar affect and gradually gaining sales and formulary adoption, Nuedexta will be studied in additional CNS indications.
Avanir Relying On PBA Drug Nuedexta For Success
Approved last year for pseudobulbar affect and gradually gaining sales and formulary adoption, Nuedexta will be studied in additional CNS indications.
Glimpse Of New Phase III Data Hints Pfizer's Eagerly-Awaited Oral RA Drug Is Still On Track
JAK inhibitor tofacitinib, formerly called tasocitinib, meets primary endpoints in second Phase III study, could be filed in second half of 2011.